|VRF||Structural Imaging Findings||Treatment Effects on VRF-Related Structural Imaging Findings||Functional Imaging Findings||Treatment Effects on VRF-Related Functional Imaging Findings|
|DM||No treatment data available.|
|Adiposity||No treatment data available.|
|Hyperlipidemia||The association between higher total cholesterol with lower rCMRglu in the precuneus, prefrontal, parietotemporal, and frontal regions remain significant after controlling for statin use (limited data).|
|Smoking||No treatment data available.|
|Metabolic syndrome||No treatment data available.|
ADC = apparent diffusion coefficient; BMI = body mass index; BP = blood pressure; CBF = cerebral blood flow; DM = diabetes mellitus; FA = fractional anisotropy; fMRI = functional magnetic resonance imaging; gCBF = global cerebral blood flow; GM = gray matter; HbA1c = glycosylated hemoglobin; HTN = hypertension; LDL = low-density lipoprotein; MAO = monoamine oxidase; MetS = metabolic syndrome; rCBF = regional cerebral blood flow; rCMRglu = regional cerebral glucose metabolic rate; SBIs = silent brain infarcts; SBP = systolic blood pressure; VRF = vascular risk factor; WM = white matter; WMHs = white matter hyperintensities.